Investor Relations Read More NYSE: VAPO 22.32 -0.11 ( -0.49% ) Pricing delayed by 20 minutes Last Updated 12/03/2021 4:00 PM Corporate Overview We are a global medical technology company focused on the development and commercialization of our proprietary Vapotherm high velocity therapy, a tool used to treat patients of all ages suffering from respiratory distress. High velocity therapy delivers noninvasive ventilatory support by providing heated, humidified and oxygenated air at a high velocity to patients through a comfortable small-bore nasal interface. Our Precision Flow systems, which deliver high velocity therapy, are clinically validated alternatives to, and address many limitations of, the current standard of care for the treatment of respiratory distress in a hospital setting. As of September 30, 2021, more than 3.2 million patients have been treated with our Precision Flow systems, and we have a global installed base of over 34,500 capital units. Latest News 11/22/2021 Vapotherm to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference READ MORE 11/03/2021 Vapotherm Reports Third Quarter 2021 Financial Results READ MORE 10/20/2021 Vapotherm to Report Third Quarter 2021 Financial Results READ MORE VIEW ALL NEWS Latest Presentation 11/10/2021 Company Overview – November 2021 DOWNLOAD PDF (OPENS IN NEW WINDOW) VIEW ALL PRESENTATIONS Latest Events There are no events scheduled. VIEW ALL EVENTS Latest Quarterly Reports VIEW ALL FINANCIAL REPORTS Contact us SEND EMAIL 603-658-0011 Quick links SEC filings Investor FAQs Investor email alerts News Events & Presentations Financial Reports SEC filings End of Day Stock UNSUBSCRIBE © 2018 VAPOTHERM PRIVACY POLICY TERMS OF USE REFERENCES Powered By Q4 Inc. 5.66.0.1 (opens in new window)